1. Introduction {#sec1}
===============

While the majority of lymphomas arise from lymph nodes, up to a quarter develop from extranodal sites \[[@B1]\]. Amongst these, primary adrenal lymphomas are considerably rare, contributing to 3% of all non-Hodgkin lymphomas and interestingly in 70% of the cases both adrenal glands are involved \[[@B2]\]. In this report, we described one such case.

2. Case Report {#sec2}
==============

Our patient is a 52-year-old Malay woman who presented with a three-week history of intermittent pyrexia. This was associated with an unintentional weight loss of 10 kg over three months. She has a past medical history of asthma, hypertension, and hyperlipidaemia.

There were no specific localizing symptoms including cough, sputum, haemoptysis, dysuria, abdominal pain, or diarrhoea. There was also no history of travel.

Parameters revealed pyrexia of 40 degrees Celsius and sinus tachycardia of 113 beats per minutes but normal blood pressure. Physical examination was unremarkable with normal heart and breath sounds. Abdomen was soft, nontender with no palpable masses. There was no cervical, axillary, or inguinal lymphadenopathy. There were no neurological deficits and stigmata of liver disease.

Initial investigations showed microcytic hypochromic anaemia with a haemoglobin of 9.8 g/dL and mean cell volume of 75.2 fL. Renal function was unremarkable, but there was a raised lactate dehydrogenase (LDH) level of 2140 U/L. Other blood results are summarised in [Table 1](#tab1){ref-type="table"}.

A computed tomography scan of the thorax abdomen and pelvis was performed, and it showed bilateral homogenous adrenal masses measuring 3.7 × 5.4 × 6.4 cm on the left and 5.5 × 2.7 × 5.9 cm on the right (Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). There was also a prominent left supraclavicular lymph node measuring 0.8 cm and a few subcentimetre mediastinal lymph nodes measuring up to 0.8 cm.

Early morning cortisol was subsequently found to be low at 242 nmol/L and short Synacthen test with 250 mcg of tetracosactide did not show adequate cortisol response ([Table 1](#tab1){ref-type="table"}). Acid Fast Bacilli stain and culture alongside with Polymerase Chain Reaction for Tuberculosis (TB PCR) of the patient was negative.

A left adrenal biopsy was performed, and histology revealed sheets of large lymphoid cells with a prominent intravascular growth pattern. The neoplastic cells were positive for CD20, CD79A, MUM1, BCL6, and BCL2. There was no expression for CD10, consistent with a nongerminal centre B-cell origin. MYC was positive in 70% of tumour cells and Ki-67 proliferation index was 90%. CD5 was positive; Cyclin D1 and SOX11 were negative, which also excludes mantle cell lymphoma. Bone marrow biopsy did not show any marrow involvement ([Figure 6](#fig6){ref-type="fig"}).

The patient was reviewed by a Hematologist, and the decision was made to manage her as for Stage 4 Diffuse Large B-Cell Lymphoma (DLBCL) in view of organ involvement. Her Eastern Cooperative Oncology Group (ECOG) status was zero, and International Prognostic Index (IPI) was one because of raised lactate dehydrogenase. She was treated with six cycles of R-CHOP and four cycles of intrathecal methotrexate chemotherapy.

Remarkably, repeat computer tomography scan after four cycles of R-CHOP chemotherapy showed interval regression of bilateral adrenal masses with nearly normal adrenal glands ([Figure 3](#fig3){ref-type="fig"}). The left enlarged supraclavicular and mediastinal nodes remained stable in size.

A Positron Emission Tomography (PET) scan six weeks after completion of both R-CHOP and intrathecal methotrexate revealed no fluorodeoxyglucose (FDG) update in the chest, abdomen, or pelvis and the enlarged left supraclavicular lymph node showed mild-FDG avidity that was smaller in size compared to previous computed tomography scans. This was discussed in a multidisciplinary tumour board, and it was decided to consider this as a reactive lymph node (please see Figures [4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}).

She remained in complete remission five months after chemotherapy and have since returned to work. However, repeat Synacthen test showed persistent adrenal insufficiency, and she remained on hydrocortisone replacement therapy. She is being monitored closely by a Hematologist and an Endocrinologist.

3. Discussion {#sec3}
=============

Primary adrenal lymphoma is a typically highly aggressive malignancy. As exemplified by our patient, most cases are usually diffuse large B-cell lymphomas and bilateral involvement is frequently observed \[[@B3]\]. Age, tumour size, adrenal insufficiency, lactate dehydrogenase level, and performance status of the patient can significantly influence prognosis \[[@B4], [@B5]\].

Diagnosis can be established with the help of biopsy and histological examination \[[@B6]\]. The European Society of Endocrinology \[[@B7]\] recommends imaging studies and hormonal assessment for bilateral adrenal masses first. This is because there are many differential diagnoses ranging from metastases from a different primary lymphomas or bilateral pheochromocytoma. In addition, there remains a possibility of cooccurrence of different entities, resulting in the necessity of separately characterising each lesion. Biopsy is recommended for hormonally inactive lesions; lesions which cannot be concluded as benign by imaging and histological diagnosis alter the management. Surgical intervention, however, is suggested to be individualised according to various factors including the patient\'s age, comorbidities, and preferences.

In our case, we elected a percutaneous needle biopsy according to patient preference. It was, therefore, reassuring that posttreatment scans showed resolution of both adrenal masses. In accordance with the works of Ichikawa et al., our patient responded well to a rituximab-containing regimen combined with intrathecal methotrexate, suggesting that this combination is effective against adrenal lymphomas \[[@B8]\].

4. Conclusion {#sec4}
=============

Bilateral adrenal lymphoma remains a rare form of non-Hodgkin lymphoma and care must be taken in ruling out other causes of bilateral adrenal masses. Subsequent surgical interventions need to be individualised. Although our experience suggests that a rituximab-containing regimen with intrathecal methotrexate is effective, larger studies should ideally be carried out to validate this treatment modality.

5. Learning Points {#sec5}
==================

Commonly bilateral adrenal masses are usually due to metastases from malignant tumours arising from lungs, breast, or colon.

Primary DLBCL affecting both adrenals is a rare phenomenon \[[@B9]\].

Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype.
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![At the time of diagnosis. Imaging studies of patient, CT thorax, and abdomen, and pelvis show bilateral adrenal masses which are homogenous measuring 3.7 × 5.4 × 6.3 cm on the left (78.3 average HU), while the right adrenal gland measures 5.5 × 2.7 × 5.9 cm (72.7 average HU).](CRIM2017-1251950.001){#fig1}

![At the time of diagnosis. Imaging studies of patient, CT thorax, and abdomen and pelvis show bilateral adrenal masses which are homogenous measuring 3.7 × 5.4 × 6.3 cm on the left (78.3 average HU), while the right adrenal gland measures 5.5 × 2.7 × 5.9 cm (72.7 average HU).](CRIM2017-1251950.002){#fig2}

![At the end of treatment. Imaging studies of the patient after having chemotherapy show interval regression of bilateral adrenal glands with both adrenal glands returning to normal size.](CRIM2017-1251950.003){#fig3}

![At the end of treatment. Posttreatment PET-CT scan showing normal sized adrenal glands (white arrows) with no significant FDG activity.](CRIM2017-1251950.004){#fig4}

![At the end of treatment. Posttreatment PET-CT scan showing a borderline enlarged left supraclavicular lymph node (white arrow) with moderate to intense FDG activity (SUVmax 8.4). In the absence of any significant adenopathy elsewhere in the body, this was deemed to be of reactive nature.](CRIM2017-1251950.005){#fig5}

![Histology images. The neoplastic lymphoid cells showed large vesicular nuclei ((a) H&E, original magnification ×600) and prominent intravascular growth pattern ((b) original magnification ×400). They were positive for CD20 ((c) original magnification ×600). CD34 stain ((d) original magnification ×400) highlighted vascular channels containing neoplastic lymphoid cells, confirming the intravascular growth pattern.](CRIM2017-1251950.006){#fig6}

###### 

Initial blood test results.

  -------------------------------------------------------------------------------
  Test                                         Results   Unit        Reference\
                                                                     interval
  -------------------------------------------- --------- ----------- ------------
  White blood cells                            6.45      ×10^9^/L    3.40--9.60

  Red blood cells                              3.87      ×10^12^/L   3.70--9.60

  Haemoglobin                                  9.8       g/dL        10.9--15.1

  Mean Cell Volume                             75.2      fL          80.0--95.0

  Mean corpuscular haemoglobin                 25.3      pg          27.0--33.0

  Mean corpuscular haemoglobin concentration   33.7      g/dL        32.0--36.0

  Haematocrit                                  29.1      \%          32.7--44.4

  Platelets                                    150       ×10^9^/L    132--372

  Mean platelet volume                         9.3       fL          8.7--12.2

  Red cell distribution width                  18.2      \%          11.4--14.8

  Sodium                                       137       mmol/L      135--145

  Potassium                                    4.4       mmol/L      3.5--5.0

  Chloride                                     101       mmol/L      95--110

  Carbon dioxide                               22        mmol/L      22--31

  Creatinine                                   66        umol/L      50--90

  Urea                                         4.9       mmol/L      2.0--6.5

  Glucose                                      7.2       mmol/L      4.0--7.8

  Albumin                                      34        g/L         38--48

  Bilirubin, total                             7         umol/L      5--30

  Bilirubin, conjugated                        1         umol/L      0--5

  Aspartate aminotransferase                   64        U/L         10--50

  Alanine aminotransferase                     48        U/L         10--70

  Alkaline Phosphatase                         162       U/L         40--130

  Lactate dehydrogenase                        2140      U/L         250--580

  Calcium, total                               2.22      mmol/L      2.15--2.55

  C-reactive protein                           65        mg/L        0--10

  Iron                                         3.3       umol/L      8.8--27.0

  Ferritin                                     1249      ug/L        10--120

  Transferrin                                  201       mg/dL       200--360

  Total iron binding capacity                  52        umol/L      52--94

  Iron saturation                              6         \%          15--50

  Thyroxine, free                              12.9      pmol/L      8.0--20.0

  Thyroid stimulating hormone                  1.59      mIU/L       0.45--4.5

  Early morning cortisol                       242       nmol/L      123--623

  Adrenocorticotropic hormone (ACTH)           3.1       pmol/L      0.0--10.2

  *Synacthen test*                                                    

  Cortisol at 0 min                            150       nmol/L       

  Cortisol at 30 min                           191       nmol/L       

  Cortisol at 60 min                           209       nmol/L       
  -------------------------------------------------------------------------------

[^1]: Academic Editor: Walter Zidek
